Clinical Trials Directory

Trials / Completed

CompletedNCT05250869

Comparative Quantification of MTX and Its Metabolites Post Glucarpidase

Comparative Quantification of MTX and Its Metabolites in Acidified vs. Non-acidified Blood Samples Post Glucarpidase Using HPLC/MS

Status
Completed
Phase
Study type
Observational
Enrollment
4 (actual)
Sponsor
Charite University, Berlin, Germany · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Acidification (i.e., addition of hydrochloric acid) of plasma samples from patients who have received Glucarpidase post high-dose MTX treatment is regarded as a necessary preanalytic step to avoid further in vitro enzymatic cleavage of MTX. However, it is unclear whether this acidification step is essential. A comparative study, which evaluates concentrations of MTX and its metabolites in paired (acidified versus non-acidified) plasma samples, has not yet been performed. Processing plasma samples without acidification would facilitate quantification of MTX, including plasma samples from patients treated at centers without adequate laboratory facilities.

Detailed description

Stored plasma samples (paired - acidified and non-acidified) from the specimens collection ('Tumorbiobank') of the Charité Comprehensive Cancer Center will be analysed by HPLC/MS. A total of 136 samples from patients post Voraxaze across 3 levels of MTX concentrations: 30 without additive, 10 with 0.9% NaCl, 30 with HCl (stored at -80C) 9 without additive, 9 with HCl (stored at +4C and analysed after 3-5 days) 9 without additive, 9 with HCl (stored at -20C and analysed after 3-5 days) 30 with HCl (stored at +4C versus ambient temperature)

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTHPLC/MSQuantification of MTX and its metabolites by HPLC/MS under various preanalytical conditions

Timeline

Start date
2022-07-06
Primary completion
2022-08-31
Completion
2022-12-31
First posted
2022-02-22
Last updated
2024-07-22

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05250869. Inclusion in this directory is not an endorsement.